Dr. Thad A. Bourque, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in Shreveport (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,218
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Louisiana State University School of Medicine in Shreveport
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
LA license MD.021311 -
Specialist
LA license 021311
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Lafayette General Medical Center Lafayette, LA
- Our Lady of Lourdes Regional Medical Center, Inc Lafayette, LA
- Opelousas General Health System Opelousas, LA
- Ochsner American Legion Hospital Jennings, LA
- Park Place Surgical Hospital Lafayette, LA
Medical groups
- Southern Urology LLC (28 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,218
- Services billed
- 48,430
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, testosterone cypionate, 1 mg | 33,100 | 18 |
| Injection, denosumab, 1 mg | 3,184 | 16 |
| Injection, onabotulinumtoxina, 1 unit | 2,800 | 19 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,301 | 880 |
| Insertion of needle into vein for collection of blood sample | 1,009 | 593 |
| Leuprolide injectable, camcevi, 1 mg | 924 | 20 |
| Automated urinalysis test | 813 | 578 |
| Psa (prostate specific antigen) measurement, total | 754 | 530 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 649 | 144 |
| Manual urinalysis test with examination using microscope, automated | 649 | 431 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Lafayette, LA | 1,017 |
| Abiraterone Acetate | 897 |
| Prednisone Other prescribers in Lafayette, LA | 861 |
| Finasteride Other prescribers in Lafayette, LA | 403 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Lafayette, LA | 293 |
| Gemtesa (vibegron) Other prescribers in Lafayette, LA | 137 |
| Myrbetriq (mirabegron) Other prescribers in Lafayette, LA | 127 |
| Nubeqa (darolutamide) | 116 |
| Cefuroxime (cefuroxime axetil) Other prescribers in Lafayette, LA | 100 |
| Xtandi (enzalutamide) | 94 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 50 payments worth $1,320 in total to this clinician.
| Bioprotect Medical, Inc. | $198 |
|---|---|
| Janssen Biotech, Inc. | $191 |
| Ferring Pharmaceuticals Inc. | $165 |
| Sumitomo Pharma America, Inc. | $151 |
| AbbVie Inc. | $125 |
| Dendreon Pharmaceuticals LLC | $120 |
| Pfizer Inc. | $80.81 |
| Merck Sharp & Dohme LLC | $66.62 |
| Food and Beverage | $1,185 |
|---|---|
| Education | $135 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. May 21, 2025 | Education ERLEADA · Oncology · in-kind | $99.99 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $35.06 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $64,380 in research payments for these studies, mostly to the institutions running them.
- Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
Janssen Research & Development, LLC - A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.